| Trial ID: | L4513 |
| Source ID: | NCT00171119
|
| Associated Drug: |
Valsartan
|
| Title: |
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension|Diabetic Nephropathy
|
| Interventions: |
DRUG: valsartan
|
| Outcome Measures: |
Primary: Change from baseline in urine albumin excretion rate after 24 weeks | Secondary: Change from baseline in urine albumin excretion rate after 24 weeks in those patients with blood pressure greater than 140/90, or who had previously taken blood pressure medicine, at study entry|Percent of patients returning to normal urine albumin excretion rate after 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
81
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2004-01
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2008-12-17
|
| Locations: |
Novartis Pharmaceuticals, Basel, Switzerland
|
| URL: |
https://clinicaltrials.gov/show/NCT00171119
|
